In preclinical studies, cotadutide demonstrated a more pronounced loss of body weight, reduction in food intake, and superior improvement in glycemic parameters in rodents compared to a GLP-1 RA
PPARs additionally regulate the canonical Wnt pathway by suppressing -catenin 23 , hence influencing intestinal differentiation and surface development
The most frequently reported adverse events with combination therapy are gastrointestinal symptoms, including nausea, vomiting, and diarrhea, which are primarily attributable to GLP-1 receptor agonists and may occur more often than with SGLT2 inhibitor monotherapy [24, 43]
Growing Need : With obesity rates rising globally, the demand for effective, minimally invasive treatments like semaglutide has surged
Interaction between the microbiota, epithelia, and immune cells in the intestine